Get the Stockscreener App
10.10
3.27%
0.32
After Hours:
10.30
0.20
+1.98%
Neogenomics Inc stock is traded at $10.10, with a volume of 3.06M.
It is up +3.27% in the last 24 hours and up +10.99% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$9.78
Open:
$9.6
24h Volume:
3.06M
Relative Volume:
0.90
Market Cap:
$1.30B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-16.29
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+1.81%
1M Performance:
+10.99%
6M Performance:
+31.17%
1Y Performance:
-28.57%
1-Day Range:
$9.60
$10.28
1-Week Range:
$9.42
$10.58
52-Week Range:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.10 | 1.27B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
565.24 | 212.23B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
213.83 | 151.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.12 | 57.84B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
146.08 | 41.02B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.96 | 36.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
Using RSI to spot recovery in NeoGenomics Inc.Bull Run & Daily Risk Controlled Trade Plans - newser.com
Will earnings trigger a reversal in NeoGenomics Inc.2025 Market Sentiment & Fast Moving Market Watchlists - newser.com
How NeoGenomics Inc. stock compares to growth peersWeekly Loss Report & Precise Swing Trade Entry Alerts - newser.com
Will a bounce in NeoGenomics Inc. offer an exitJuly 2025 Reactions & High Accuracy Investment Signals - newser.com
Chart overlay techniques for tracking NeoGenomics Inc.2025 Price Action Summary & Expert Curated Trade Ideas - newser.com
Sector ETF performance correlation with NeoGenomics Inc.Weekly Volume Report & Fast Gain Swing Alerts - newser.com
Developing predictive dashboards with NeoGenomics Inc. dataJuly 2025 Sentiment & Safe Entry Point Alerts - newser.com
Will NeoGenomics Inc. (NG9) stock announce a stock splitMarket Performance Report & Long-Term Capital Growth Ideas - newser.com
Price momentum metrics for NeoGenomics Inc. explained2025 Volatility Report & Expert Curated Trade Setups - newser.com
Is NeoGenomics Inc. trending in predictive chart models2025 Investor Takeaways & Community Consensus Trade Signals - newser.com
NeoGenomics Q3 2025 Earnings: Revenue Beat Offset by EPS Miss and Margin PressureNews and Statistics - IndexBox
How analysts rate NeoGenomics Inc. stock today2025 Price Action Summary & AI Based Trade Execution Alerts - newser.com
The Top 5 Analyst Questions From NeoGenomics’s Q3 Earnings Call - Yahoo Finance
Technical analysis overview for NeoGenomics Inc. stockJuly 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
Is NeoGenomics Inc. (NG9) stock supported by free cash flow2025 Price Momentum & Weekly High Potential Alerts - newser.com
NeoGenomics (NEO): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Is NeoGenomics Inc. stock affected by interest rate hikesEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
NeoGenomics, Inc. (NEO) Stock Forecasts - Yahoo Finance
Candlestick signals on NeoGenomics Inc. stock todayTrade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will NeoGenomics Inc. price bounce be sustainableJuly 2025 EndofMonth & Safe Capital Growth Tips - newser.com
Will NeoGenomics Inc. stock recover faster than marketJuly 2025 Momentum & Consistent Profit Alerts - newser.com
Price action breakdown for NeoGenomics Inc.2025 Volume Leaders & Weekly Stock Performance Updates - newser.com
Will NeoGenomics Inc. (NG9) stock keep raising dividendsQuarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Tools to assess NeoGenomics Inc.’s risk profileRecession Risk & Verified High Yield Trade Plans - newser.com
Is NeoGenomics Inc. stock a bargain at current levelsEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
How hedge fund analytics apply to NeoGenomics Inc. stockBear Alert & Low Risk High Reward Trade Ideas - newser.com
How to track smart money flows in NeoGenomics Inc.Jobs Report & Free Technical Pattern Based Buy Signals - newser.com
Visualizing NeoGenomics Inc. stock with heatmapsJuly 2025 Spike Watch & Reliable Price Breakout Alerts - newser.com
Forecasting NeoGenomics Inc. price range with options dataJuly 2025 Recap & Low Risk Growth Stock Ideas - newser.com
NeoGenomics to present RaDaR ST bridging study at ISLB 2025 - MSN
Will NeoGenomics Inc. stock gain from government policiesProfit Target & Intraday High Probability Setup Alerts - newser.com
Regression analysis insights on NeoGenomics Inc. performanceJuly 2025 Short Interest & Growth Focused Entry Reports - newser.com
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
How NeoGenomics Inc. (NG9) stock responds to bond marketJuly 2025 Reactions & Safe Capital Preservation Plans - newser.com
NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges - MSN
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
6.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):